<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561691</url>
  </required_header>
  <id_info>
    <org_study_id>OSAG101-BSC05</org_study_id>
    <nct_id>NCT00561691</nct_id>
  </id_info>
  <brief_title>Nimotuzumab in Children With Intrinsic Pontine Glioma</brief_title>
  <official_title>Phase III Study on the Effectiveness of OSAG 101 (Theraloc®)in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncoscience AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Medical Hospital, University of Bonn, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dept. of Statistics, University of Dortmund, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRM Biometrics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Medical Hospital, Medical School Hannover, Hannover, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Medical Hospital, University of Leipzig, Leipzig, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Medical Hospital, University of Muenster, Muenster, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Burdenko Neurosurgery Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Nazinonale Tumori, Div. of Paediatric Oncology,Milano, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncoscience AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of efficiency of nimotuzumab in children with diffuse intrinsic pontine glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the poor prognosis of diffuse intrinsic pontine gliomas, the limited therapy options,&#xD;
      the relevant portion of EGFR expression and the unexpected good response to the therapy with&#xD;
      OSAG 101 in the phase II study, a phase III study was planned in newly diagnosed diffuse&#xD;
      intrinsic pontine gliomas in children and adolescents. A phase II study in patients of&#xD;
      recurrence/resistance high grade glioma in childhood or adolescence showed that, in&#xD;
      particular, a part of the intrinsic pontine glioma response to the monotherapy with OSAG 101&#xD;
      resulting in a reduction in the size of the tumour or stabilisation in the growth of the&#xD;
      tumour. Together with clinical improvement, stabilisation lasted markedly over 6 months in&#xD;
      two thirds of the patients. The current phase III study was scheduled to provide evidence of&#xD;
      the effectiveness in the case of newly diagnosed intrinsic pontine glioma. In this study,&#xD;
      OSAG 101 will be given concomitantly to the only standard therapy for this kind of tumour,&#xD;
      i.e. the fractionated radiotherapy, to show effectiveness in the primary endpoint of median&#xD;
      progression-free survival, the secondary endpoint of median overall survival and the side&#xD;
      effect profile.&#xD;
&#xD;
      Evidence from the median progression-free survival and the side effect profile of this&#xD;
      combination met the expected results and one may consider that combination therapy of this&#xD;
      therapeutic approach with other immunotherapeutic or antiangiogenic approaches and/or mild&#xD;
      chemotherapy could lead to a better prognosis and quality of life for these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the progression-free survival (PFS) of the combination of monoclonal anti-EGFR antibody OSAG 101 and standard local radiotherapy</measure>
    <time_frame>week 12, 24, 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the objective response rate (R=CR+PR+SD/Nr) according to RECIST To determine the duration of response and the overall survival To assess adverse events and the toxicity profile according to CTCAE version 3.0</measure>
    <time_frame>week 12, 24, 36</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Diffuse Instrinsic Ponitine Glioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nimotuzumab</intervention_name>
    <description>monoclonal antibody</description>
    <other_name>Theraloc</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        children and adolescents&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histology and staging of disease:&#xD;
&#xD;
          -  Newly diagnosed intrinsic pontine glioma documented by MRI and measurable in at least&#xD;
             one dimension&#xD;
&#xD;
          -  Histology is not required for this study, tumour biopsy is not recommended General&#xD;
             conditions&#xD;
&#xD;
          -  Age ≥ 3 years to ≤ 20 years, both gender&#xD;
&#xD;
          -  Life expectancy ≥ 4 weeks&#xD;
&#xD;
          -  Performance status ECOG ≥ 3 or Karnofsky/Lansky status ≥ 40%&#xD;
&#xD;
          -  Adequate haematological, renal, and hepatic function Absolute leukocyte count ≥ 2.0 x&#xD;
             109/l Haemoglobin ≥ 10 g/dl Platelets ≥ 50 x 109/l Bilirubin total ≤ 2.5 x ULN ALT/AST&#xD;
             ≤ 5.0 x ULN Creatinine i. S. ≤ 1.5 x ULN&#xD;
&#xD;
        Prior/initial examinations (within 14 days prior to the start of therapy):&#xD;
&#xD;
          -  Cranial MRI (estimation of index lesion)&#xD;
&#xD;
          -  Clinical internal and neurological examination; body weight, height, surface,&#xD;
             Performance status by ECOG, Karnofsky or Lansky&#xD;
&#xD;
          -  Blood cell count, blood gas analysis; serum analysis for electrolytes (Na, K, Ca, Mg),&#xD;
             chloride, phosphate, creatinine, BUN, AST, ALT, bilirubin, GGT, LDH, lipase, total&#xD;
             protein, CRP, blood sugar; coagulation test (Quick, PTT, TT); urinalysis&#xD;
&#xD;
          -  EKG, echocardiography in case of positive cardiac history&#xD;
&#xD;
          -  Pregnancy test in females of childbearing age Other criteria&#xD;
&#xD;
          -  Planned day of first antibody application within 14 days after MRI&#xD;
&#xD;
          -  Written and signed informed consent from patient and/or parents or legal&#xD;
             guardian(s)(s) after being informed&#xD;
&#xD;
          -  Negative pregnancy test in females of childbearing age&#xD;
&#xD;
          -  Treatment in a study centre&#xD;
&#xD;
          -  Availability of the patient during the study treatment and the ability to comply with&#xD;
             the study plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pontine glioma as secondary malignancy&#xD;
&#xD;
          -  Low grade brain stem glioma (i.e. focal, cervicomedullar, tectal brain stem glioma)&#xD;
&#xD;
          -  Other severe underlying disease or pre-existing serious conditions which bear the risk&#xD;
             of an inadequate study treatment (e.g. severe mental retardation, severe statomotoric&#xD;
             retardation, severe cerebral palsy, congenital syndromes)&#xD;
&#xD;
          -  Prior antineoplastic therapy, inclusively chemotherapy, immunotherapy, radiotherapy&#xD;
&#xD;
          -  Prior administration of a recombinant human or mural antibody or known&#xD;
             hypersensitivity to antibodies&#xD;
&#xD;
          -  Simultaneous antineoplastic therapy other than the study treatment&#xD;
&#xD;
          -  Participation in another therapeutic study or experimental treatment involving the&#xD;
             underlying cancer disease&#xD;
&#xD;
          -  Pregnancy, lactating mother and inadequate contraception in females and males of&#xD;
             childbearing age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udo Bode, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Bonn, Children's Medical Hospital</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://ukb.uni-bonn.de</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diffuse instrinsic ponitine glioma, brainstem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

